|
 "Under the terms of the agreement, Xencor is receiving a $150
million upfront payment from Novartis and the two companies will
equally share the cost to jointly develop two Xencor antibodies
targeting the CD3 domain," Novartis said.
Novartis would additionally receive rights to develop and
commercialize four further bispecific antibodies and to use Xencor's
antibody technology in up to 10 additional molecules, the companies
said.
While Xencor would retain full commercial rights in the United
States, Novartis would receive commercial rights outside the United
States.
(Reporting by Brenna Hughes Neghaiwi; Editing by Stephen Coates)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
